Focus on Diabetes Care

Back to articles

Selecting a third-line agent for type 2 diabetes

KEY POINT

According to a meta-analysis published in a recent issue of Annals of Internal Medicine, there is no apparent difference between antihyperglycemic drug classes added as a third therapeutic option for patients with type 2 diabetes who are already taking metformin and a sulfonylurea.